COST-EFFECTIVENESS OF UMECLIDINIUM/VILANTEROL (UMEC/VI) VERSUS ACLIDINIUM/FORMOTEROL (ACL/ FOR) IN PATIENTS WITH COPD IN THE UNITED KINGDOM

被引：0
|
作者：
Shah, D. [1 ]
Martin, A. [2 ]
Kendall, R. [3 ]
Noorduyn, S. G. [4 ]
Dasari, P. [5 ]
Risebrough, N. [6 ]
Ismaila, A. [7 ]
机构：
[1] ICON plc, Jersey City, NJ USA
[2] GSK, Brentford, England
[3] ICON Plc, Vancouver, BC, Canada
[4] GSK, Value Evidence & Outcomes, Mississauga, ON, Canada
[5] ICON Plc, Houston, TX USA
[6] ICON Plc, Toronto, ON, Canada
[7] GSK, Value Evidence & Outcomes, Collegeville, PA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE708
引用
收藏
页码：S190 / S191
页数：2
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF UMECLIDINIUM/VILANTEROL (UMEC/VI) VERSUS TIOTROPIUM/OLODATEROL (TIO/OLO) IN PATIENTS WITH COPD: UNITED KINGDOM PAYER PERSPECTIVE
    Kendall, R.
    Martin, A.
    Shah, D.
    Noorduyn, S. G.
    Dasari, P.
    Risebrough, N.
    Ismaila, A.
    VALUE IN HEALTH, 2023, 26 (12) : S191 - S191
  • [2] Cost-Effectiveness of Umeclidinium/Vilanterol (UMEC/VI) Versus Glycopyrrolate/Formoterol Fumarate (GLY/FOR) in Symptomatic Patients with COPD in the UK: The AERISTO trial
    Ismaila, Afisi S.
    Shah, Dhvani
    Martin, Alan
    Kendall, Robyn
    Noorduyn, Stephen
    Dasari, Priyadarsini
    Risebrough, Nancy A.
    Compton, Chris
    Noorduyn, Stephen G.
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [3] COST EFFECTIVENESS OF UMECLIDINIUM/VILANTEROL (UMEC/VI) COMBINATION THERAPY AMONG SYMPTOMATIC COPD PATIENTS
    Punekar, Y. S.
    Roberts, G.
    Ismaila, A.
    O'Leary, M.
    VALUE IN HEALTH, 2014, 17 (07) : A595 - A595
  • [4] COST-EFFECTIVENESS OF UMECLIDINIUM/VILANTEROL IN SYMPTOMATIC COPD SPANISH PATIENTS
    Miravitlles, M.
    Galdiz, J. B.
    Huerta, A.
    Villacampa, A.
    Carcedo, D.
    Garcia-Rio, F.
    VALUE IN HEALTH, 2015, 18 (07) : A500 - A501
  • [5] Cost-Effectiveness of Umeclidinium/Vilanterol Versus Indacaterol/Glycopyrronium in Symptomatic patients with COPD in the UK
    Ismaila, Afisi S.
    Shah, Dhvani
    Martin, Alan
    Kendall, Robyn
    Noorduyn, Stephen
    Dasari, Priyadarsini
    Risebrough, Nancy A.
    Compton, Chris
    Noorduyn, Stephen G.
    Risebrough, Nancy A.
    Compton, Chris
    Noorduyn, Stephen G.
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [6] Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients
    Miravitlles, Marc
    Galdiz, Juan B.
    Huerta, Alicia
    Villacampa, Alba
    Carcedo, David
    Garcia-Rio, Francisco
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2016, 11 : 123 - 132
  • [7] Comparative Assessment Of Umeclidinium/vilanterol (umec/vi) Combination Therapy Among Symptomatic Patients With COPD
    Huisman, E.
    Ismaila, A.
    Naya, I.
    Karabis, A.
    Punekar, Y. S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [8] Comparative assessment of umeclidinium/vilanterol (UMEC/VI) combination therapy among symptomatic COPD patients
    Huisman, Eline
    Cockle, Sarah
    Punekar, Yogesh
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [9] Cost-effectiveness of Budesonide/Glycopyrrolate/Formoterol Fumarate (BGF) Versus Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) to Treat COPD Based on Mortality Risk Reduction From a Matching-adjusted Indirect Treatment Comparison
    Parsekar, K.
    Pandey, S.
    Tansey-Dwyer, D.
    Marshall, J.
    Rustignoli, I.
    Pollack, M.
    Singh, B.
    Ouwens, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [10] BENEFIT-RISK PROFILES OF FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL (FF/UMEC/VI) VS UMEC/VI IN PATIENTS WITH COPD: A MARKOV MODEL
    Bratton, Daniel
    Hartley, Benjamin
    Barnes, Neil
    Brusselle, Guy
    Compton, Christopher
    Corbridge, Thomas
    Dransfield, Mark
    Halpin, David
    Han, Meilan
    Jones, Christine Elaine
    Jones, Paul
    Lange, Peter
    Lipson, David
    Martinez, Fernando
    Papi, Alberto
    Roche, Nicolas
    Singh, Dave
    Wise, Robert
    CHEST, 2020, 158 (04) : 1666A - 1671A
12345